Namwiwat Medical PCLBKK:NAM 39 PS Ratio is 1.41 as of Jul. 12, 2026, which is 48% below its 10-year median of 2.69. GuruFocus rates BKK:NAM with a GF Score™ of 39/100 and a GF Value™ of ฿6.03 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks better than 72.55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Namwiwat Medical PCL's share price is ฿3.44.
Namwiwat Medical PCL's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ฿2.44. Hence, Namwiwat Medical PCL's PS Ratio for today is 1.41.
Good Sign:
Namwiwat Medical Corp PCL stock PS Ratio (=1.41) is close to 3-year low of 1.31.
The historical rank and industry rank for Namwiwat Medical PCL's PS Ratio or its related term are showing as below:
BKK:NAM'
s PS Ratio Range Over the Past 10 Years
Min: 1.31 Med: 2.69 Max: 15.41
Current: 1.41
During the past 6 years, Namwiwat Medical PCL's highest PS Ratio was 15.41. The lowest was 1.31. And the median was 2.69.
BKK:NAM's PS Ratio is ranked better than 72.55% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs BKK:NAM: 1.41
During the past 6 years, Namwiwat Medical PCL's highest 3-Year average Revenue per Share Growth Rate was 19.40% per year. The lowest was 4.00% per year. And the median was 11.70% per year.
Back to Basics: PS Ratio
Namwiwat Medical PCL (BKK:NAM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Namwiwat Medical PCL PS Ratio Related Terms
Namwiwat Medical PCL PS Ratio Historical Data
* Premium members only.
The historical data trend for Namwiwat Medical PCL's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Namwiwat Medical PCL's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's PS Ratio distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Namwiwat Medical PCL's Share Price of today is ฿3.44. Namwiwat Medical PCL's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿2.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Namwiwat Medical PCL (BKK:NAM) has a PS Ratio of 1.41 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Namwiwat Medical PCL and its competitors. This is 48% below median its historical median of 2.69. Over the past decade, Namwiwat Medical PCL's PS Ratio has ranged from 1.31 to 15.41. According to the industry distribution chart, Namwiwat Medical PCL ranks #221 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 27.5%.
Is Namwiwat Medical PCL's PS Ratio too high?
Namwiwat Medical PCL's current PS Ratio of 1.41 is 48% below median its 10-year median of 2.69. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 15.41. The Medical Devices & Instruments industry median PS Ratio is 2.94. Namwiwat Medical PCL's value of 1.41 is 52% below this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #221 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #221 out of 805 companies for PS Ratio. This puts Namwiwat Medical PCL in the upper half of its industry. The industry median PS Ratio is 2.94. Namwiwat Medical PCL's value of 1.41 is 52% below this benchmark. Historically, Namwiwat Medical PCL's own PS Ratio has ranged from 1.31 to 15.41 over the past decade. While the company's 10-year median is 2.69 vs. the industry median of 2.94, Namwiwat Medical PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current PS Ratio of 1.41 is 52% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current PS Ratio is 1.41, which is 48% below median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.03, compared to a current price of ฿3.44 — trading 43% below its estimated fair value. The current PS Ratio is 1.41, which is 48% below median its 10-year median of 2.69 and 52% below the Medical Devices & Instruments industry median of 2.94. Namwiwat Medical PCL's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current PS Ratio is 1.41 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.44 is trading 43% below its estimated GF Value™ of ฿6.03.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
PS Ratio: 1.41 (48% below median its 10-year median of 2.69)
GF Value™: ฿6.03 vs. price of ฿3.44 (43% below fair value)
Industry Position: 52% below the Medical Devices & Instruments median (#221 of 805)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
39GF Score
Get the complete analysis for BKK:NAM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
